Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model

Molecular Oncology

Volumn 8, Issue 2, 2014, Pages 351-365

  Stratmann, Anna T ^a   Fecher, David ^a   Wangorsch, Gaby ^b   Göttlich, Claudia ^a   Walles, Thorsten ^a   Walles, Heike ^a   Dandekar, Thomas ^b   Dandekar, Gudrun ^a   Nietzer, Sarah L ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

3D tumor model; Boolean model; EMT; Invasion; Personalized medicine; Targeted therapy

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; GEFITINIB; KI 67 ANTIGEN; MUCIN 1; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CELL PROLIFERATION; CELL STRUCTURE; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFORMATION SCIENCE; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; THREE DIMENSIONAL MODEL; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL EXPERIMENT; ANIMAL TISSUE; CELL CULTURE; CELL GROWTH; NONHUMAN; SIGNAL TRANSDUCTION; THREE DIMENSIONAL IMAGING; TISSUE ENGINEERING;

3D TUMOR MODEL; BOOLEAN MODEL; EMT; INVASION; PERSONALIZED MEDICINE; TARGETED THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; QUINAZOLINES; SIGNAL TRANSDUCTION; SWINE; TUMOR MICROENVIRONMENT;

EID: 84894387037     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.11.009     Document Type: Article

References (58)

1. Aubert S., Fauquette V., Hemon B., Lepoivre R., Briez N., Bernard D., Van Seuningen I., Leroy X., Perrais M. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Res. 2009, 69:5707-5715.
2. Audretsch C., Lopez D., Srivastava M., Wolz C., Dandekar T. A semi-quantitative model of Quorum-Sensing in Staphylococcus aureus, approved by microarray meta-analyses and tested by mutation studies. Mol. Biosyst. 2013.
3. Boyanova D., Nilla S., Birschmann I., Dandekar T., Dittrich M. PlateletWeb: a systems biologic analysis of signaling networks in human platelets. Blood 2012, 119:e22-34.
4. Bronte G., Rizzo S., La Paglia L., Adamo V., Siragusa S., Ficorella C., Santini D., Bazan V., Colucci G., Gebbia N., Russo A. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev. 2010, 36(Suppl 3):S21-S29.
5. Cheng T.M., Gulati S., Agius R., Bates P.A. Understanding cancer mechanisms through network dynamics. Brief Funct. Genomics 2012, 11:543-560.
6. Cree I.A., Glaysher S., Harvey A.L. Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr. Opin. Pharmacol. 2010, 10:375-379.
7. Cullen P.J. Signaling mucins: the new kids on the MAPK block. Crit. Rev. Eukaryot. Gene Expr. 2007, 17:241-257.
8. da Cunha Santos G., Shepherd F.A., Tsao M.S. EGFR mutations and lung cancer. Annu. Rev. Pathol. 2011, 6:49-69.
9. Di Cara A., Garg A., De Micheli G., Xenarios I., Mendoza L. Dynamic simulation of regulatory networks using SQUAD. BMC Bioinformatics 2007, 8:462.
10. Engelman J.A., Mukohara T., Zejnullahu K., Lifshits E., Borras A.M., Gale C.M., Naumov G.N., Yeap B.Y., Jarrell E., Sun J., Tracy S., Zhao X., Heymach J.V., Johnson B.E., Cantley L.C., Janne P.A. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Invest. 2006, 116:2695-2706.
11. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., Janne P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
12. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
13. Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D. Lung cancer cell lines as tools for biomedical discovery and research. J. Natl. Cancer Inst. 2010, 102:1310-1321.
14. Gill B.J., Gibbons D.L., Roudsari L.C., Saik J.E., Rizvi Z.H., Roybal J.D., Kurie J.M., West J.L. A synthetic matrix with independently tunable biochemistry and mechanical properties to study epithelial morphogenesis and EMT in a lung adenocarcinoma model. Cancer Res. 2012, 72:6013-6023.
15. Gonzalez-Rodriguez D., Guevorkian K., Douezan S., Brochard-Wyart F. Soft matter models of developing tissues and tumors. Science 2012, 338:910-917.
16. Haga Y., Hiroshima K., Iyoda A., Shibuya K., Shimamura F., Iizasa T., Fujisawa T., Ohwada H. Ki-67 expression and prognosis for smokers with resected stage I non-small cell lung cancer. Ann. Thorac. Surg. 2003, 75:1727-1732. discussion 1732-1723.
17. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
18. Ho S.B., Shekels L.L., Toribara N.W., Kim Y.S., Lyftogt C., Cherwitz D.L., Niehans G.A. Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium. Cancer Res. 1995, 55:2681-2690.
19. Hutmacher D.W., Horch R.E., Loessner D., Rizzi S., Sieh S., Reichert J.C., Clements J.A., Beier J.P., Arkudas A., Bleiziffer O., Kneser U. Translating tissue engineering technology platforms into cancer research. J. Cell Mol. Med. 2009, 13:1417-1427.
20. Kokubo Y., Gemma A., Noro R., Seike M., Kataoka K., Matsuda K., Okano T., Minegishi Y., Yoshimura A., Shibuya M., Kudoh S. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br. J. Cancer 2005, 92:1711-1719.
21. Lamb J. The connectivity Map: a new tool for biomedical research. Nat. Rev. Cancer 2007, 7:54-60.
22. Lara-Guerra H., Chung C.T., Schwock J., Pintilie M., Hwang D.M., Leighl N.B., Waddell T.K., Tsao M.S. Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer. Lung Cancer 2012, 76:235-241.
23. Lau S.K., Weiss L.M., Chu P.G. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am. J. Clin. Pathol. 2004, 122:61-69.
24. Linke K., Schanz J., Hansmann J., Walles T., Brunner H., Mertsching H. Engineered liver-like tissue on a capillarized matrix for applied research. Tissue Eng. 2007, 13:2699-2707.
25. Lopez-Ferrer A., Curull V., Barranco C., Garrido M., Lloreta J., Real F.X., de Bolos C. Mucins as differentiation markers in bronchial epithelium. Squamous cell carcinoma and adenocarcinoma display similar expression patterns. Am. J. Respir. Cell Mol. Biol. 2001, 24:22-29.
26. Lutolf M.P., Hubbell J.A. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat. Biotechnol. 2005, 23:47-55.
27. Mischnik M., Boyanova D., Hubertus K., Geiger J., Philippi N., Dittrich M., Wangorsch G., Timmer J., Dandekar T. A Boolean view separates platelet activatory and inhibitory signalling as verified by phosphorylation monitoring including threshold behaviour and integrin modulation. Mol. Biosyst. 2013, 9:1326-1339.
28. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., Sunpaweravong P., Han B., Margono B., Ichinose Y., Nishiwaki Y., Ohe Y., Yang J.J., Chewaskulyong B., Jiang H., Duffield E.L., Watkins C.L., Armour A.A., Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361:947-957.
29. Morris M.K., Saez-Rodriguez J., Sorger P.K., Lauffenburger D.A. Logic-based models for the analysis of cell signaling networks. Biochemistry 2010, 49:3216-3224.
30. Mukohara T., Engelman J.A., Hanna N.H., Yeap B.Y., Kobayashi S., Lindeman N., Halmos B., Pearlberg J., Tsuchihashi Z., Cantley L.C., Tenen D.G., Johnson B.E., Janne P.A. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J. Natl. Cancer Inst. 2005, 97:1185-1194.
31. Nakajima Y., Takagi H., Kakizaki S., Horiguchi N., Sato K., Sunaga N., Mori M. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells. Anticancer Res. 2012, 32:5251-5262.
32. Naseem M., Philippi N., Hussain A., Wangorsch G., Ahmed N., Dandekar T. Integrated systems view on networking by hormones in Arabidopsis immunity reveals multiple crosstalk for cytokinin. Plant Cell 2012, 24:1793-1814.
33. Noro R., Gemma A., Kosaihira S., Kokubo Y., Chen M., Seike M., Kataoka K., Matsuda K., Okano T., Minegishi Y., Yoshimura A., Kudoh S. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. BMC Cancer 2006, 6:277.
34. Oda K., Matsuoka Y., Funahashi A., Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol. 2005, 1:2005 0010.
35. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
36. Pao W., Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 2010, 10:760-774.
37. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M., Zakowski M.F., Heelan R.T., Kris M.G., Varmus H.E. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005, 2:e17.
38. Paszek M.J., Zahir N., Johnson K.R., Lakins J.N., Rozenberg G.I., Gefen A., Reinhart-King C.A., Margulies S.S., Dembo M., Boettiger D., Hammer D.A., Weaver V.M. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005, 8:241-254.
39. Philippi N., Walter D., Schlatter R., Ferreira K., Ederer M., Sawodny O., Timmer J., Borner C., Dandekar T. Modeling system states in liver cells: survival, apoptosis and their modifications in response to viral infection. BMC Syst. Biol. 2009, 3:97.
40. Philippi N.R., Bird C.E., Marcus N.J., Olson E.B., Chesler N.C., Morgan B.J. Time course of intermittent hypoxia-induced impairments in resistance artery structure and function. Respir. Physiolo. Neurobiol. 2010, 170:157-163.
41. Riely G.J., Marks J., Pao W. KRAS mutations in non-small cell lung cancer. Proc. Am. Thorac. Soc. 2009, 6:201-205.
42. Saez-Rodriguez J., Alexopoulos L.G., Zhang M., Morris M.K., Lauffenburger D.A., Sorger P.K. Comparing signaling networks between normal and transformed hepatocytes using discrete logical models. Cancer Res. 2011, 71:5400-5411.
43. Schanz J., Pusch J., Hansmann J., Walles H. Vascularised human tissue models: a new approach for the refinement of biomedical research. J. Biotechnol. 2010, 148:56-63.
44. Schlatter R., Philippi N., Wangorsch G., Pick R., Sawodny O., Borner C., Timmer J., Ederer M., Dandekar T. Integration of Boolean models exemplified on hepatocyte signal transduction. Brief Bioinformatics 2012, 13:365-376.
45. Schultheiss D., Gabouev A.I., Cebotari S., Tudorache I., Walles T., Schlote N., Wefer J., Kaufmann P.M., Haverich A., Jonas U., Stief C.G., Mertsching H. Biological vascularized matrix for bladder tissue engineering: matrix preparation, reseeding technique and short-term implantation in a porcine model. J. Urol. 2005, 173:276-280.
46. Sequist L.V., Heist R.S., Shaw A.T., Fidias P., Rosovsky R., Temel J.S., Lennes I.T., Digumarthy S., Waltman B.A., Bast E., Tammireddy S., Morrissey L., Muzikansky A., Goldberg S.B., Gainor J., Channick C.L., Wain J.C., Gaissert H., Donahue D.M., Muniappan A., Wright C., Willers H., Mathisen D.J., Choi N.C., Baselga J., Lynch T.J., Ellisen L.W., Mino-Kenudson M., Lanuti M., Borger D.R., Iafrate A.J., Engelman J.A., Dias-Santagata D. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann. Oncol. 2011, 22:2616-2624.
47. Singh A., Greninger P., Rhodes D., Koopman L., Violette S., Bardeesy N., Settleman J. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009, 15:489-500.
48. Smalley K.S., Lioni M., Herlyn M. Life isn't flat: taking cancer biology to the next dimension. In Vitro Cell Dev. Biol. Anim. 2006, 42:242-247.
49. Sos M.L., Michel K., Zander T., Weiss J., Frommolt P., Peifer M., Li D., Ullrich R., Koker M., Fischer F., Shimamura T., Rauh D., Mermel C., Fischer S., Stuckrath I., Heynck S., Beroukhim R., Lin W., Winckler W., Shah K., LaFramboise T., Moriarty W.F., Hanna M., Tolosi L., Rahnenfuhrer J., Verhaak R., Chiang D., Getz G., Hellmich M., Wolf J., Girard L., Peyton M., Weir B.A., Chen T.H., Greulich H., Barretina J., Shapiro G.I., Garraway L.A., Gazdar A.F., Minna J.D., Meyerson M., Wong K.K., Thomas R.K. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J. Clin. Invest. 2009, 119:1727-1740.
50. Tian M., Schiemann W.P. The TGF-beta paradox in human cancer: an update. Future Oncol. 2009, 5:259-271.
51. Tsvetkova E., Goss G.D. Drug resistance and its significance for treatment decisions in non-small-cell lung cancer. Curr. Oncol. 2012, 19:S45-S51.
52. Tursz T., Andre F., Lazar V., Lacroix L., Soria J.C. Implications of personalized medicine-perspective from a cancer center. Nat. Rev. Clin. Oncol. 2011, 8:177-183.
53. Ventura A.C., Jackson T.L., Merajver S.D. On the role of cell signaling models in cancer research. Cancer Res. 2009, 69:400-402.
54. Walles T., Weimer M., Linke K., Michaelis J., Mertsching H. The potential of bioartificial tissues in oncology research and treatment. Onkologie 2007, 30:388-394.
55. Wangorsch G., Butt E., Mark R., Hubertus K., Geiger J., Dandekar T., Dittrich M. Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation. BMC Syst. Biol. 2011, 5:178.
56. Wu V.W., Tam K.W., Tong S.M. Evaluation of the influence of tumor location and size on the difference of dose calculation between ray tracing algorithm and Fast Monte Carlo algorithm in stereotactic body radiotherapy of non-small cell lung cancer using CyberKnife. J. Appl. Clin. Med. Phys. 2013, 14:4280.
57. Yamada K.M., Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007, 130:601-610.
58. Zhang R., Shah M.V., Yang J., Nyland S.B., Liu X., Yun J.K., Albert R., Loughran T.P. Network model of survival signaling in large granular lymphocyte leukemia. Proc. Natl. Acad. Sci. U S A 2008, 105:16308-16313.